Ventana Medical Systems Inc., a member of the Roche Group, announced a new agreement with Quintiles Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. This is great news for patients as China is one of the only countries in the world that requires all patient samples be tested in China, even those used in clinical trials.“Our new relationship with Quintiles to offer companion diagnostic testing services in China moves our mission, to improve the lives of all patients afflicted with cancer, a big step forward,” said Doug Ward, VP and Companion Diagnostics Lifecycle Leader. “Our oncology pharma collaborators can now reach a large and growing number of patients that can benefit from clinical trial participation using targeted treatments and tests.”
According to the World Health Organization (WHO)’s latest World Cancer Report, China had the highest rate of new cancer cases recorded globally in 2012 with 21.9%, or 3.07 million, and the trend is increasing, particularly in lung, liver, esophageal and stomach cancers1. This underscores the growing need for patients in China to have in-country access to the most advanced tissue diagnostic testing and companion therapeutics in the industry, which starts with early phase clinical trials.
“It’s been extremely important to Ventana that we find a strategic laboratory in China that will help us uphold the CAP testing standard of excellence set by our global companion diagnostic CAP/CLIA laboratory in Tucson, Arizona, USA,” said Dr. H. James Hnatyszyn, director Laboratory Operations for VENTANA companion diagnostic services. “Quintiles has the experience, infrastructure and qualified personnel to meet this challenge.”
Date: August 5, 2014
Source: Ventana Medical Systems
